SWOT Analysis for TG Therapeutics Inc

Companies with 10% increase in share price over three months, with rising net profit growth
High Normalized Momentum Score
Consistent Highest Return Stocks over Five Years - Nifty500
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Week
Expensive Rockets (DVM)
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
Weekly Strategy: High Momentum Score Stocks (subscription)
Annual Profit Growth higher than Sector Profit Growth
High Momentum Scores (Technical Scores greater than 50)
Good quarterly growth in the recent results
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Near 52 Week High
Increasing Revenue every Quarter for the past 4 Quarters
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Stock gained more than 20% in one month
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
RSI indicating price strength
Stocks near 52 Week High with Significant Volumes
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter

Stocks in the PE Sell Zone
PE higher than Industry PE
PEG greater than Industry PEG
High PE (PE > 40)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Top Losers
Low Piotroski Score : Companies with weak financials
Top Losers
Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV